13 completed, 7 recruiting, 6 not yet recruiting, 4 unknown. 11 Phase 1, 9 Not applicable, 6 Phase 2, 3 Early Phase 1, 2 Phase 3.
Follow Malignant Tumors: new trials by email Literature Review of Malignant Tumors trials Research Report on Malignant Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LM-364 as a Single Agent or in Combination With Anti-tumor Therapy in Patients With Advanced Solid Tumors LM-364 for injection, Tislelizumab - Malignant Tumors | Phase 1 / Phase 2 | Not yet recruiting | LaNova Medicines Limited | 90 | 2026-07-15 | 2026-07-10 |
| Correlation Analysis of Gene Characteristics of Malignant Tumors With Prognosis Immunotherapy Therapy, Radiation Therapy, Radical surgery - Malignant Tumors | Recruiting | Nanfang Hospital, Southern Medical University | 500 | 2026-05-29 | 2026-06-03 | |
| 125I Seed Brachytherapy Combined With Immunotherapy for Primary, Recurrent, or Metastatic Malignant Tumors Immune Checkpoint Inhibitors, 125I Seed Implantation - Malignant Tumors | Phase 2 | Not yet recruiting | Li Min | 90 | 2026-01-01 | 2026-01-06 |
| PET/CT-Guided Biological Target Volume Delineation and Dose Optimization for Radioactive Seed Implantation Therapy in Malignant Tumors CT-Guided Radioactive Seed Implantation, PET/CT-Guided Radioactive Seed Implantation, PET/CT-Guided Radioactive Seed Implantation (Biological Dose Optimization) - Malignant Tumors | Not applicable | Not yet recruiting | Li Min | 90 | 2026-01-01 | 2026-01-08 |
| Exploring Gut Microbiome Differences in Female Cancer Patients With Varied Ovarian Function and Fertility Outcomes Following Immune Checkpoint Inhibitor Therapy No Intervention: Observational Cohort - Malignant Tumors | Not yet recruiting | West China Second University Hospital | 40 | 2025-10-10 | 2025-10-01 | |
| A Study of LM-350 in Subjects With Advanced Solid Tumours LM-350 for injection - Malignant Tumors | Phase 1 / Phase 2 | Recruiting | LaNova Medicines Limited | 80 | 2025-08-28 | 2026-01-26 |
| The Predictive Value of Serum Histone Succinylation in Malignant Solid Tumors Malignant Tumors | Not yet recruiting | Yinghua Ji | 1000 | 2025-08-20 | 2025-08-20 | |
| Clinical Application of 68Ga-FL-031 PET in the Diagnosis and Staging of Malignant Tumors Injection of 68Ga-FL-031, Injection of 18F-FDG - Malignant Tumors, SSTR2 | Early Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 10 | 2025-06-12 | 2025-12-24 |
| Application of KRAS Vaccine in the Treatment of KRAS-mutated Malignancies KRAS-mutated mRNA vaccine, TORIPALIMAB, Pemetrexed+carboplatin - Malignant Tumors | Phase 1 | Recruiting | Sichuan University | 20 | 2025-06-05 | 2025-06-24 |
| A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors SSS59 - Malignant Tumors | Phase 1 | Recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | 154 | 2025-04-27 | 2025-04-29 |
| Clinical Application of 99mTc-FDPH46 SPECT/CT Imaging in Malignant Solid Tumor: a Prospective Exploratory Study 99mTc-FDPH46 SPECT/CT Imaging - Malignant Tumors, Solid Tumor Malignancy | Not yet recruiting | Zhejiang University | 20 | 2024-12-28 | 2024-12-31 | |
| Study of LM-299 in Subjects Advanced Malignant Tumors LM-299 - Malignant Tumors | Phase 1 / Phase 2 | Recruiting | LaNova Medicines Limited | 108 | 2024-10-09 | 2025-05-02 |
| Application of mRNA Immunotherapy Technology in Epstein-Barr Virus-related Refractory Malignant Tumors EBV mRNA vaccine - Malignant Tumors | Phase 1 | Active not recruiting | West China Hospital | 19 | 2023-02-08 | 2025-06-04 |
| A Phase I/II Study of LM-101 Injection in Patients With Advanced Malignant Tumors LM101, Toripalimab, Rituximab - Malignant Tumors | Phase 1 / Phase 2 | Recruiting | LaNova Medicines Limited | 139 | 2023-01-11 | 2024-12-19 |
| A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors LBL-007 Injection, Tislelizumab Injection, Cisplatin Injection - Malignant Tumors | Phase 1 / Phase 2 | Completed | Nanjing Leads Biolabs Co.,Ltd | 98 | 2022-09-01 | 2026-04-01 |
| FAP PET/CT or PET/MR Production in the Diagnosis, Staging, and Efficacy Assessment of Malignant Tumors Application 68Ga-Fibroblast activation protein inhibitor - Malignant Tumors, Positron-Emission Tomography | Not applicable | Completed | The First Affiliated Hospital of Anhui Medical University | 22 | 2022-04-28 | 2025-08-13 |
| BBPA PET/CT in Patients With Malignant Tumors BBPA PET examination - Malignant Tumors | Not applicable | Unknown | Peking Union Medical College Hospital | 30 | 2021-03-22 | 2024-04-01 |
| CAR - γ δ T Cells in the Treatment of Relapsed and Refractory CD7 Positive T Cell-derived Malignant Tumors Chimeric antigen receptor modified γδ T cells - CAR, Malignant Tumors | Early Phase 1 | Unknown | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 8 | 2020-06-03 | 2021-03-08 |
| The Feasibility of Multispectral Optoacoustic Tomography in Different Diseases Multispectral optoacoustic tomography - Sjogren Syndrome, Malignant Tumors | Not applicable | Completed | University Medical Center Groningen | 20 | 2020-04-07 | 2024-12-18 |
| Clinical Study of Pretreatment PET/CT Parameters for Predicting the Efficacy of 125I Seed Implantation in the Treatment of Malignant Tumors Malignant Tumors | Completed | Jiangxi Provincial Cancer Hospital | 41 | 2019-01-01 | 2025-10-06 |
Showing 20 of 32. Sign in to see all of them.
Neoplasms (32) · Cerebrovascular Disorders (1) · Disease (1) · Metabolic Diseases (1) · Neurilemmoma (1) · Postoperative Complications (1) · Recurrence (1) · Sjogren's Syndrome (1) · Vascular Malformations (1)
Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Cardiovascular Diseases (2) · Arthritis (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Brain Diseases (1) · Cardiovascular Abnormalities (1) · Central Nervous System Diseases (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Connective Tissue Diseases (1) · Disease Attributes (1) · Dry Eye Syndromes (1) · Eye Diseases (1)
Injections (3) · tislelizumab (2) · toripalimab (2) · 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1) · Bioseal (1) · Cisplatin (1) · Diet, Ketogenic (1) · Docetaxel (1) · Gemcitabine (1) · Immune Checkpoint Inhibitors (1) · Immunonutrition Diet (1) · Nivolumab (1) · Nutritional Support (1) · Radiotherapy (1) · Rituximab (1)
LaNova Medicines Limited (4) · Li Min (2) · Assistance Publique - Hôpitaux de Paris (1) · Bristol-Myers Squibb (1) · China-Japan Friendship Hospital (1) · Dana-Farber Cancer Institute (1) · Guangzhou Bioseal Biotechnology Co., Ltd. (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · InnoPharmax Inc. (1) · Jiangxi Provincial Cancer Hospital (1) · Medical University of Vienna (1) · Nanfang Hospital, Southern Medical University (1) · Nanjing Leads Biolabs Co.,Ltd (1) · Peking Union Medical College Hospital (1) · PersonGen BioTherapeutics (Suzhou) Co., Ltd. (1)
China (20) · Australia (3) · United States (3) · France (2) · Austria (1) · Japan (1) · Netherlands (1) · South Korea (1) · Taiwan (1)
Min Li, Dr. (2) · Chia-Chi Lin, MD (1) · Herve Rubie, MD (1) · Huiqin Xu (1) · Michael Frass, Prof. Dr. (1) · Milos Janicek, MD, PhD (1) · Nashat Y. Gabrail, MD (1) · Peng Xingchen (1) · Richard Kocharian, MD, PhD (1) · Ryoo In Seon, dotorate (1) · Sharad Ghamande, MD (1) · Steven Rowe, M.D., Ph.D (1) · Xiaoli Lan (1)
PMID 12183436, PMID 12542520, PMID 15767544, PMID 16549957, PMID 17363526, PMID 17575208, PMID 18570153, PMID 19721715, PMID 19817894, PMID 19872213, PMID 20009446, PMID 20558056, PMID 22236832, PMID 22371645, PMID 22614695, PMID 25523036, PMID 29650248, PMID 30072500, PMID 30850501, PMID 31230828, PMID 32169911, PMID 32598906, PMID 33010094, PMID 33778675, PMID 34904839, PMID 35011496, PMID 35450755, PMID 36477400, PMID 36879039, PMID 36972467, PMID 36986521, PMID 37083360, PMID 37895905, PMID 38193393, PMID 38320123, PMID 38695960, PMID 41910591, PMID 42180616, PMID 42720799, PMID 9065413
P50CA103175 (1)